Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABSW) FCF Margin (2021 - 2025)

SAB Biotherapeutics' FCF Margin history spans 5 years, with the latest figure at 26435.23% for Q4 2025.

  • For Q4 2025, FCF Margin rose 3479420.0% year-over-year to 26435.23%; the TTM value through Dec 2025 reached 18604.82%, up 2122347.0%, while the annual FY2024 figure was 2618.65%, 148794.0% down from the prior year.
  • FCF Margin reached 26435.23% in Q4 2025 per SABSW's latest filing, down from 30144.19% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 30144.19% in Q3 2025 to a low of 8358.96% in Q4 2024.
  • Average FCF Margin over 5 years is 2895.52%, with a median of 79.69% recorded in 2022.
  • Peak YoY movement for FCF Margin: crashed -567563bps in 2023, then skyrocketed 3479420bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 65.47% in 2021, then dropped by -18bps to 77.41% in 2022, then crashed by -5624bps to 4430.85% in 2023, then crashed by -89bps to 8358.96% in 2024, then surged by 416bps to 26435.23% in 2025.
  • Per Business Quant, the three most recent readings for SABSW's FCF Margin are 26435.23% (Q4 2025), 30144.19% (Q3 2025), and 11114.37% (Q2 2025).